New research from the University of Sydney in Australia has revealed a concerning rise in newborns being affected by antibiotic-resistant infections. These infections, previously thought to mainly impact older babies, are now affecting infants within days of birth. The study analyzed nearly 15,000 blood samples from sick infants in 2019 and 2020 across five Southeast Asian countries, including Indonesia and the Philippines.
The researchers found that a significant portion of the infections identified were resistant to existing treatments recommended by the World Health Organization. This is exacerbated by the lack of new antimicrobial drugs specifically developed for newborns. Associate Professor Phoebe Williams, the senior author of the study, emphasized the urgent need to update guidelines based on local bacterial profiles and resistance patterns to address the rising mortality rates.
Antibiotics are crucial medications for treating bacterial infections, but their effectiveness is threatened by antibiotic resistance. The study demonstrated that gram-negative bacteria, such as Acinetobacter and E. coli, were responsible for 80% of the infections, posing a higher risk of spreading and developing resistance.
The research team is calling for an immediate overhaul of diagnostic and treatment guidelines for newborns in these regions. They highlighted the challenge of relying on outdated data from different demographics and the lengthy process of developing new antibiotics for infant use. Co-author Michelle Harrison stressed the need for region-specific surveillance to guide treatment decisions and prevent a reversal of progress in reducing child mortality rates.
The study also revealed a significant rate of fungal infections in newborns, underscoring the importance of prescribing effective treatments to save infants’ lives. The findings emphasize the critical need for tailored interventions to address the growing threat of antibiotic-resistant infections in newborns.